Clinical Edge Journal Scan

Maternal atopic dermatitis linked with the risk for childhood- and adult-onset atopic dermatitis


 

Key clinical point: Maternal atopic dermatitis (AD) significantly increases the risk for both childhood- and adult-onset AD, and active smoking is the main lifestyle risk factor for adult-onset AD.

Major finding: Compared with non-atopic and atopic control individuals, individuals with a maternal AD family history had a significantly higher risk for childhood-onset (adjusted odds ratio [aOR] 4.36, 95% CI 1.18-16.17; and aOR 32.97, 95% CI 4.03-269.68, respectively) and adult-onset AD (aOR 15.79, 95% CI 1.81-137.74; and aOR 34.15, 95% CI 3.15-370.28, respectively) and active smokers had an increased risk for adult-onset AD (aOR 5.54, 95% CI 1.06-29.01; and aOR 4.03, 95% CI 1.20-13.45, respectively).

Study details: This study analyzed the cross-sectional data of 736 adult individuals with childhood-onset (<18 years) or adult-onset (≥18 years) AD and 76 non-atopic and 91 atopic control individuals without AD.

Disclosures: This study was funded by the Christine Kühne-Center for Allergy Research and Education (CK-CARE), Switzerland. Some authors declared various ties, including employment, with CK-CARE or others.

Source: Maintz L et al. Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood. Allergy. 2023 (Mar 22). Doi: 10.1111/all.15721

Recommended Reading

New data forecast more oral PDE4 inhibitors for psoriasis
MDedge Dermatology
Air pollution may be causing eczema
MDedge Dermatology
Topical delgocitinib shows promise for chronic hand eczema, pivotal trial shows
MDedge Dermatology
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
MDedge Dermatology
Commentary: IL-31 inhibitor, e-cigarettes, and upadacitinib in AD, April 2023
MDedge Dermatology
What are the clinical implications of recent skin dysbiosis discoveries?
MDedge Dermatology
Phase 3 trials support lebrikizumab for moderate-to-severe atopic dermatitis
MDedge Dermatology
Baricitinib shows promise in pediatric patients with moderate-to-severe atopic dermatitis
MDedge Dermatology
Baricitinib allows flexibility in dosing regimens up to 104 weeks in moderate-to-severe atopic dermatitis
MDedge Dermatology
Topical tacrolimus and corticosteroids show similar efficacy and impact on airways in childhood atopic dermatitis
MDedge Dermatology